Opportunity Information: Apply for RFA DK 20 502
This NIH funding opportunity (RFA-DK-20-502) is a limited competition cooperative agreement intended to keep the Diabetes Prevention Program Outcomes Study (DPPOS) moving forward by supporting its Biostatistics Research Center (BRC). The core idea is continuity: the BRC is expected to maintain and strengthen long-term follow-up of the original Diabetes Prevention Program (DPP) participant cohort so investigators can keep learning how early prevention strategies play out over decades, not just a few years. Because this is a collaborative U01 mechanism and is listed as a clinical trial required, the award is designed for close, ongoing coordination with NIH program staff and with the broader DPPOS network rather than a hands-off, investigator-only grant.
The scientific foundation for the work is the landmark DPP, a large multi-center controlled clinical trial that tested whether type 2 diabetes could be prevented or delayed in people at high risk. The DPP showed that intensive lifestyle intervention aimed at weight loss cut the onset of type 2 diabetes by about 58% compared with placebo, while metformin reduced diabetes onset by about 31% compared with placebo. After the DPP ended, the same cohort transitioned into the DPPOS to evaluate longer-term outcomes, including continued diabetes development and diabetes-related microvascular complications. Over time, the research focus has broadened in a practical way as the cohort has aged: the current phase emphasizes long-range questions such as whether early metformin exposure influences later cancer and cardiovascular disease risk, and more generally how chronic diseases emerge and progress in a diverse, deeply characterized population.
The main purpose of funding the DPPOS BRC is to ensure the statistical and data coordination backbone remains strong enough to support ongoing cohort follow-up and complex longitudinal analyses. As the cohort gets older, the opportunity expands beyond diabetes incidence alone to include heterogeneity in aging-related and chronic disease trajectories. The FOA highlights continued exploration of contributors to multiple chronic conditions, specifically naming areas such as cognitive impairment, cancer, and diabetes vascular complications, while also leaving room for other chronic outcomes that can be rigorously studied in this cohort. A central question running through the project is whether the original DPP interventions (lifestyle change and metformin) have lasting preventive effects on these later-life conditions, either directly or through their impact on diabetes risk and metabolic health over time.
This announcement is paired with a companion FOA (RFA-DK-20-501) that supports the continuation of the DPPOS Clinical Centers, while RFA-DK-20-502 focuses on the Biostatistics Research Center role. In practical terms, that means the BRC awardee is expected to work in a tightly integrated way with the clinical sites to support consistent data collection, management, quality control, and analysis across the network. The cooperative agreement structure signals that NIH anticipates active involvement in the conduct and coordination of the study, reflecting the scale and importance of maintaining a long-running national cohort and ensuring standardized methods across centers.
Eligibility is restricted. The opportunity lists public and state-controlled institutions of higher education as eligible applicants, and it explicitly states that non-U.S. (foreign) institutions cannot apply and that non-domestic components of U.S. organizations are also not eligible to apply. At the same time, foreign components as defined by the NIH Grants Policy Statement may be allowed, which generally means limited, well-justified international involvement could be included under certain circumstances, but the applicant organization itself must meet the stated U.S.-based eligibility requirements.
Key administrative details from the source information include that the sponsor is the National Institutes of Health, the funding instrument is a cooperative agreement (U01), the opportunity category is discretionary, and the CFDA numbers associated with the program are 93.393, 93.847, and 93.866. The original closing date listed is July 22, 2020, and the opportunity was created on January 23, 2020. While the excerpt does not provide an award ceiling or the expected number of awards, the limited competition framing and the highly specific continuation purpose make clear that this FOA is meant to sustain an established, unique national resource rather than launch an open-ended new research program.Apply for RFA DK 20 502
- The National Institutes of Health in the education, food and nutrition, health sector is offering a public funding opportunity titled "Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.847, 93.866.
- This funding opportunity was created on 2020-01-23.
- Applicants must submit their applications by 2020-07-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): NIH RFA-DK-20-502 (DPPOS Biostatistics Research Center)
What is NIH RFA-DK-20-502?
RFA-DK-20-502 is a National Institutes of Health (NIH) funding opportunity announcement (FOA) for a limited competition cooperative agreement (U01) to support the Biostatistics Research Center (BRC) for the Diabetes Prevention Program Outcomes Study (DPPOS).
What is the main purpose of this funding opportunity?
The purpose is to keep the DPPOS moving forward by maintaining and strengthening the statistical and data coordination infrastructure (the BRC) needed for long-term follow-up of the original Diabetes Prevention Program (DPP) participant cohort and for complex longitudinal analyses over decades.
Why does this FOA emphasize "continuity"?
This FOA is designed to sustain an established, long-running national cohort and its supporting infrastructure. The BRC is expected to provide the backbone that enables consistent, standardized follow-up and analysis as the cohort ages, rather than starting a brand-new, open-ended research program.
What is the Diabetes Prevention Program (DPP) and why is it important here?
The DPP was a landmark large multi-center controlled clinical trial that tested whether type 2 diabetes could be prevented or delayed in people at high risk. It provides the scientific foundation for DPPOS and the need for continued coordinated follow-up and analysis.
What did the DPP find about lifestyle intervention and metformin?
In the DPP, an intensive lifestyle intervention aimed at weight loss reduced the onset of type 2 diabetes by about 58% compared with placebo, and metformin reduced diabetes onset by about 31% compared with placebo.
What is the Diabetes Prevention Program Outcomes Study (DPPOS)?
DPPOS is the long-term follow-up study that continued after the DPP ended. It follows the same participant cohort to evaluate longer-term outcomes, including continued diabetes development and diabetes-related microvascular complications, and broader outcomes as the cohort ages.
What types of outcomes are emphasized in the current phase of DPPOS?
As the cohort has aged, the focus has broadened to long-range outcomes and aging-related trajectories. The FOA specifically highlights chronic conditions and outcomes such as cognitive impairment, cancer, and diabetes vascular complications, and it allows for other chronic outcomes that can be rigorously studied in this cohort.
What is a key scientific question running through this project?
A central question is whether the original DPP interventions (lifestyle change and metformin) have lasting preventive effects on later-life conditions, either directly or indirectly through their long-term effects on diabetes risk and metabolic health.
What is the Biostatistics Research Center (BRC) expected to do under this FOA?
The BRC is expected to provide the statistical and data coordination backbone for DPPOS, supporting ongoing cohort follow-up and complex longitudinal analyses. It is also expected to work in an integrated way with clinical sites on consistent data collection, data management, quality control, and analysis across the network.
How does this FOA relate to the DPPOS Clinical Centers?
This announcement is paired with a companion FOA, RFA-DK-20-501, which supports continuation of the DPPOS Clinical Centers. RFA-DK-20-502 specifically focuses on the Biostatistics Research Center role that supports and coordinates network-wide data and analyses.
What does it mean that this award uses a cooperative agreement (U01) mechanism?
A U01 cooperative agreement indicates that NIH expects close, ongoing coordination between the awardee and NIH program staff, as well as collaboration with the broader DPPOS network. It is not intended to be a hands-off, investigator-only grant.
Is this funding opportunity considered a clinical trial?
Yes. The FOA is listed as "clinical trial required," indicating that the funded work is expected to align with NIH clinical trial requirements as described for this opportunity.
Who is eligible to apply?
Eligibility is restricted. The FOA lists public and state-controlled institutions of higher education as eligible applicants.
Can non-U.S. (foreign) institutions apply?
No. The FOA explicitly states that non-U.S. (foreign) institutions cannot apply.
Are non-domestic components of U.S. organizations eligible to apply?
No. The FOA states that non-domestic components of U.S. organizations are not eligible to apply.
Are any international elements allowed at all?
The FOA notes that foreign components, as defined by the NIH Grants Policy Statement, may be allowed. This generally suggests that limited, well-justified international involvement could be included in some circumstances, but the applicant organization itself must meet the stated U.S.-based eligibility requirements.
Who is the sponsoring agency?
The sponsor is the National Institutes of Health (NIH).
What is the opportunity category?
The opportunity category is discretionary.
What are the CFDA numbers associated with this opportunity?
The CFDA numbers listed are 93.393, 93.847, and 93.866.
When was this opportunity created and when did it close?
The opportunity was created on January 23, 2020. The original closing date listed is July 22, 2020.
Is the award size (ceiling) or number of awards provided in the information given?
No. The excerpt does not provide an award ceiling or the expected number of awards.
What does "limited competition" imply for this FOA?
Based on the description, limited competition and the highly specific continuation purpose indicate this FOA is meant to sustain an established, unique national resource (the DPPOS infrastructure) rather than fund a broad, open competition for unrelated new programs.
Browse more opportunities from the same category: Education, Food and Nutrition, Health
Next opportunity: Supporting Independent Media
Previous opportunity: COPS-CHP-APPLICATION-2020
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 20 502
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 20 502) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required) Apply for RFA DK 20 501 Funding Number: RFA DK 20 501 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional) Apply for PAR 20 125 Funding Number: PAR 20 125 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required) Apply for PAR 20 134 Funding Number: PAR 20 134 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $200,000 |
| Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed) Apply for RFA AI 20 035 Funding Number: RFA AI 20 035 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $3,500,000 |
| Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) Apply for RFA OD 20 016 Funding Number: RFA OD 20 016 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional) Apply for PAR 20 315 Funding Number: PAR 20 315 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) Apply for PAR 21 068 Funding Number: PAR 21 068 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) Apply for PAR 21 069 Funding Number: PAR 21 069 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $200,000 |
| Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43 Clinical Trial Optional) Apply for RFA TW 21 004 Funding Number: RFA TW 21 004 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) Apply for PAR 21 246 Funding Number: PAR 21 246 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required) Apply for RFA NS 22 002 Funding Number: RFA NS 22 002 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) Apply for RFA MD 22 004 Funding Number: RFA MD 22 004 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Education Program on Translational Devices (R25 Clinical Trial Not Allowed) Apply for PAR 22 146 Funding Number: PAR 22 146 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $250,000 |
| Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required) Apply for RFA DK 22 014 Funding Number: RFA DK 22 014 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $500,000 |
| Interventions that Address Structural Racism to Reduce Kidney Health Disparities Research Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA DK 22 015 Funding Number: RFA DK 22 015 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $500,000 |
| Interventions that Address Structural Racism to Reduce Kidney Health Disparities Research Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA DK 23 003 Funding Number: RFA DK 23 003 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Centers for AIDS Research (P30 Clinical Trial Not Allowed) Apply for PAR 23 116 Funding Number: PAR 23 116 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed) Apply for PAR 23 117 Funding Number: PAR 23 117 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) Apply for PAR 23 191 Funding Number: PAR 23 191 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $275,000 |
| Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional) Apply for PAR 23 190 Funding Number: PAR 23 190 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 20 502", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.